Biotechnology

Choosing the wrong regulatory partner can derail a market launch. A new guide from Q&C Services offers a veteran's roadmap for de-risking expansion.

Azitra is betting its future on a radical pivot, leveraging its science for cosmetics and biotech tools. Is this a savvy move for faster cash or a risky dilution of focus?

A new survey reveals the deep toll of canine skin allergies on pets and owners, exposing a massive unmet need that has pharmaceutical giants racing for a cure.

ARMR Sciences reports a major breakthrough in the fight against overdose, but can a preventative vaccine truly turn the tide on the fentanyl crisis?

Adaptive Biotechnologies' sophisticated convertible note offering isn't just about capital; it's a strategic de-risking of its finances to accelerate its fight against cancer.

A new collaboration aims to weaponize the immune system against tough GI cancers. We break down the science, strategy, and nearly $800M per program deal.

Researchers at Children's Hospital of Philadelphia have pioneered a personalized cartilage graft that could revolutionize surgery for a life-threatening infant airway condition.

FiberSense AG’s new 28-day CGM sensor just won European approval, challenging market leaders. But the real growth signal is its plan to move beyond glucose.

A Swedish pharma company's trial is progressing faster than expected, but the real story is the potential paradigm shift for millions suffering from a neglected disease.

A new AU$481M deal with Everest Medicines brings a promising FSGS drug closer to 1M Asian patients, part of a larger, de-risked global strategy.

With 33% growth dwarfing industry norms, NNB Nutrition's integrated model and fermentation tech aren't just winning—they're rewriting the rules for wellness.

Assertio Holdings delists from Nasdaq after its merger with Zydus. A deep dive into the strategic calculus and the crucial decision facing its debt holders.

Biotech firm Azitra is leveraging its engineered microbe tech to tackle rare diseases and enter the $71B cosmeceutical market. Is this a brilliant pivot or a risky bet?

A new study validates iMDx's precision diagnostic tech, setting the stage for a strategic assault on the centralized lab model for organ rejection monitoring.

Opus Genetics unveils a multi-program gene therapy pipeline, backed by a robust financial runway, aiming to systematically dismantle inherited retinal diseases.

Verastem Oncology's new drug enters a pivotal trial for pancreatic cancer, targeting a notorious mutation with a novel dual-action mechanism.

A new alliance between Sun Life and Medzown moves beyond financial safety nets, using AI to steer patients to clinical trials and reshape corporate healthcare.

New appointments bring deep legal and pharma expertise to Canada's Patented Medicine Prices Review Board, signaling a pivotal moment under new 2026 guidelines.

A new bill named for a man failed by the system aims to modernize medical psilocybin access. But can it overcome bureaucratic inertia and position Canada as a leader?

As a rare Ebola strain rages in a DRC warzone, the G7 pledges massive aid. But with fragile peace deals and no proven cure, is it enough to stop a global crisis?